Patents by Inventor Markus Albers

Markus Albers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biphenyl and biphenyl-analogous compounds as integrin antagonists
    Patent number: 6677360
    Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: January 13, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
  • Cyclic carboxylic acids as integrin antagonists
    Publication number: 20030232868
    Abstract: The present invention relates to compounds of general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.
    Type: Application
    Filed: May 12, 2003
    Publication date: December 18, 2003
    Inventors: Thomas Lehmann, Rudiger Fischer, Markus Albers, Thomas Rolle, Gerhard Muller, Gerhard Hessler, Masaomi Tajimi, Karl Ziegelbauer, Hiromi Okigami, Kevin Bacon, Haruki Hasegawa
  • Novel cytostatic conjugates with integrin ligands
    Publication number: 20020193311
    Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.
    Type: Application
    Filed: March 8, 2002
    Publication date: December 19, 2002
    Inventors: Hans-Georg Lerchen, Jorg Baumgarten, Andreas Schoop, Markus Albers
  • Cytostatic-integrin conjugates having specifically cleavable linking units
    Publication number: 20020183256
    Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selevtively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.
    Type: Application
    Filed: December 21, 2001
    Publication date: December 5, 2002
    Inventors: Hans-Georg Lerchen, Jorg Baumgarten, Oswald Lockhoff, Markus Albers, Andreas Schoop
  • Biphenyl and biphenyl-analogous compounds as integrin antagonists
    Patent number: 6420396
    Abstract: The present invention relates to 2-Mesitylsulfonylamino-3-{3′[(pyridinylamino)methyl][1,1-biphenyl]-4-yl}propanoic acid, pharmaceutical compositions thereof, their preparation, their use in the treatment of cancer, arteriosclerosis, restenosis, osteolytic disorders, ophthalmic disorders, and their use as integrin antagonists.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: July 16, 2002
    Assignee: Beiersdorf AG
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
  • Biphenyl and biphenyl-analogous compounds as integrin antagonists
    Publication number: 20020016461
    Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.
    Type: Application
    Filed: April 6, 2001
    Publication date: February 7, 2002
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Harter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jorg Keldenich, Ulf Brueggemeier, Klemens Lustig